Skip to main content
. 2016 Sep 7;113(38):E5618–E5627. doi: 10.1073/pnas.1608384113

Fig. S3.

Fig. S3.

Anti-PDGFRα treatment of T241-PDGF-BB tumors. (A) Endomucin+ tumor vessels (red) and αSMA+ cells (green) and endomucin+ tumor vessels (red) and FSP1+ stromal fibroblasts (green) in buffer- or anti-PDGFRα–treated T241-PDGF-BB tumors. (Scale bar, 100 μm.) (B) Quantification of αSMA+ myofibroblsts (n = 12 fields per group) and FSP1+ fibroblasts (n = 12 fields per group) in buffer- or anti-PDGFRα–treated T241-PDGF-BB tumors. N.S., not significant. (C) CD31+ (red) vessels and NG2+ pericyte (green) signals in buffer- or anti-PDGFRα–treated T241-PDGF-BB tumors. Arrows point to vessel-disassociated pericytes. (Scale bar, 50 μm.) (D) Quantification of CD31+ microvessel density (n = 7 fields per group), pericyte coverage (n = 7 fields per group), and pericyte numbers (n = 7 fields per group). N.S., not significant. (E) Tumor growth curves in buffer- or anti-PDGFRα–treated T241-PDGF-BB tumor-bearing mice (n = 4–6 animals per group). Data are represented as mean ± SEM. N.S., not significant.